GO:0047045 testosterone dehydrogenase (NADP+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047045 describes the NADP+-dependent oxidation of testosterone to androst-4-ene-3,17-dione, a key step in steroid hormone metabolism.
• The reaction is catalyzed by 17beta-hydroxysteroid dehydrogenase (17beta-HSD) enzymes that use NADP+ as the preferred cofactor.
• Guinea-pig liver testosterone 17beta-dehydrogenase (NADP+) was among the first enzymes purified and shown to also exhibit benzene dihydrodiol dehydrogenase activity.
• Structural studies of human 3alpha-hydroxysteroid dehydrogenase type 3 and 3alpha-hydroxysteroid/dihydrodiol dehydrogenase have revealed how testosterone and NADP+ bind in the active site.
• Environmental organotins such as triphenyltin and tributyltin inhibit testicular 17beta-hydroxysteroid dehydrogenase, suppressing testosterone biosynthesis.
• AKR1C3 (17beta-HSD5) is a NADP+-dependent enzyme that has been targeted for selective inhibitors to overcome EGFR C797S-mediated osimertinib resistance in non-small cell lung cancer.
Description
GO:0047045, testosterone dehydrogenase (NADP+) activity, is a molecular function defined by the catalysis of the reaction NADP+ + testosterone = NADPH + H+ + androst-4-ene-3,17-dione. This activity is central to the regulation of androgen levels because it converts the active androgen testosterone into the less potent androstenedione, thereby modulating hormone action in peripheral tissues and in steroidogenic organs. The enzyme class responsible for this activity belongs to the 17beta-hydroxysteroid dehydrogenase (17beta-HSD) family, which includes multiple isoforms with distinct cofactor preferences and substrate specificities. Researchers study GO:0047045 because it directly influences the bioavailability of testosterone and other androgens, which in turn affects processes ranging from male sexual development to cancer progression. For example, inhibition of testicular 17beta-hydroxysteroid dehydrogenase by organotin compounds reduces testosterone biosynthesis, linking environmental toxicants to endocrine disruption. In cancer, NADP+-dependent 17beta-HSD activity, particularly that of AKR1C3, has been implicated in resistance to targeted therapies, making it a candidate for drug development. Understanding the molecular details of GO:0047045 requires integrating enzymology, structural biology, and cell-based models. The availability of crystal structures for related enzymes bound to testosterone and NADP+ has provided a template for rational inhibitor design and for probing the catalytic mechanism. This article synthesizes the current knowledge of GO:0047045, its associated genes, regulatory features, disease relevance, and the experimental methods used to study it.
testosterone dehydrogenase (NADP+) activity At A Glance
| GO ID | GO:0047045 |
|---|---|
| GO term | testosterone dehydrogenase (NADP+) activity |
| Ontology | molecular_function |
| Synonym | 17beta-hydroxysteroid:NADP+ 17-oxidoreductase activity; 17-ketoreductase activity; NADP-dependent testosterone-17beta-oxidoreductase activity; testosterone 17beta-dehydrogenase (NADP+); testosterone 17-beta-dehydrogenase (NADP+) activity |
| Definition | Catalysis of the reaction: NADP+ + testosterone = NADPH + H+ + androst-4-ene-3,17-dione. |
| Major function | NADP+-dependent oxidation of testosterone to androstenedione, regulating androgen levels. |
| Cofactor | NADP+ (nicotinamide adenine dinucleotide phosphate, oxidized form) |
| Substrate | Testosterone (17beta-hydroxyandrost-4-en-3-one) |
| Product | Androst-4-ene-3,17-dione (androstenedione) and NADPH |
What Is GO:0047045?
Testosterone dehydrogenase (NADP+) activity is the ability of an enzyme to catalyze the reversible oxidation of testosterone to androst-4-ene-3,17-dione using NADP+ as the electron acceptor, producing NADPH and a proton. This activity is classified as a molecular function in the Gene Ontology and is synonymous with 17beta-hydroxysteroid:NADP+ 17-oxidoreductase activity, 17-ketoreductase activity, and NADP-dependent testosterone-17beta-oxidoreductase activity. The reaction specifically targets the 17beta-hydroxyl group of testosterone, converting it to a ketone at the C17 position of the steroid nucleus.
Why Is testosterone dehydrogenase (NADP+) activity Important in Cell Biology?
GO:0047045 is important because it governs a critical step in androgen metabolism that determines the local and systemic concentrations of testosterone and its derivatives. By converting testosterone to androstenedione, this activity can attenuate androgen receptor signaling, which is relevant to prostate cancer, benign prostatic hyperplasia, and androgen deficiency disorders. Moreover, the NADP+-preference distinguishes this activity from NAD+-dependent 17beta-HSD isoforms, allowing for selective targeting in therapeutic contexts. The enzyme activity is also a target of endocrine-disrupting chemicals, as shown by the inhibition of testicular 17beta-hydroxysteroid dehydrogenase by organotins, which can suppress testosterone biosynthesis. In oncology, NADP+-dependent 17beta-HSD enzymes such as AKR1C3 contribute to intratumoral androgen synthesis and have been linked to resistance to EGFR inhibitors in non-small cell lung cancer, highlighting the clinical relevance of this GO term.
• Regulates testosterone bioavailability by converting it to androstenedione, thereby modulating androgen receptor signaling.
• Distinguishes NADP+-dependent 17beta-HSD isoforms from NAD+-dependent isoforms, enabling selective inhibitor design.
• Plays a role in testicular testosterone biosynthesis, as inhibition of 17beta-HSD reduces testosterone production.
• Contributes to intratumoral androgen synthesis in castration-resistant prostate cancer and other hormone-dependent cancers.
• Is a target for endocrine-disrupting chemicals such as triphenyltin and tributyltin, which suppress enzyme activity.
• Provides a structural template for drug discovery, with crystal structures of related enzymes bound to testosterone and NADP+.
• Involved in the cross-talk between adrenal and Leydig cell steroids, influencing overall steroidogenic output.
• Serves as a biomarker for steroidogenic enzyme activity in liver and gonadal tissues.
• Has been linked to resistance to EGFR C797S-mediated osimertinib resistance in non-small cell lung cancer through AKR1C3.
• Enables mechanistic studies of 17beta-hydroxysteroid dehydrogenase kinetics and cofactor specificity.
What Happens During testosterone dehydrogenase (NADP+) activity?
Substrate binding and cofactor recruitment
In simple terms: The enzyme first grabs testosterone and NADP+ so they are positioned correctly for the reaction.
The catalytic cycle begins with the binding of testosterone and the oxidized cofactor NADP+ to the enzyme active site. Structural studies of related 3alpha-hydroxysteroid dehydrogenases have shown that testosterone occupies a hydrophobic pocket, while NADP+ is anchored by hydrogen bonds to the phosphate groups and the nicotinamide ring. The binding is ordered, with cofactor binding often preceding steroid binding, although the exact sequence can vary among isoforms.
Hydride transfer and oxidation
In simple terms: The enzyme removes a hydride from testosterone and gives it to NADP+, turning testosterone into androstenedione.
Once bound, the 17beta-hydroxyl group of testosterone is oxidized to a ketone. This involves the transfer of a hydride ion from the C17 position of the steroid to the C4 position of the nicotinamide ring of NADP+, forming NADPH. A proton is released into the solvent. The reaction is reversible, but under physiological conditions the NADP+-dependent oxidation is favored when NADP+ is abundant. The catalytic residues typically include a tyrosine and a lysine that stabilize the transition state.
Product release and enzyme turnover
In simple terms: After the reaction, the enzyme releases androstenedione and NADPH so it can start over.
Following hydride transfer, the products androst-4-ene-3,17-dione (androstenedione) and NADPH are released from the active site. The enzyme can then undergo another round of catalysis. The release of NADPH may be rate-limiting, and the intracellular ratio of NADP+/NADPH can influence the direction of the reaction. In tissues with high NADP+ levels, the oxidative direction predominates, reducing testosterone concentrations.
Isoform-specific variations
In simple terms: Different enzymes can do this reaction, but they may prefer different cofactors or have different speeds.
Multiple 17beta-hydroxysteroid dehydrogenase isoforms can catalyze this reaction, but they differ in cofactor preference, tissue distribution, and substrate specificity. For example, the guinea-pig liver enzyme was originally described as a testosterone 17beta-dehydrogenase (NADP+) that also exhibits benzene dihydrodiol dehydrogenase activity, indicating broad substrate acceptance. In contrast, human AKR1C3 (17beta-HSD5) is a NADP+-dependent enzyme that preferentially reduces androstenedione to testosterone in some contexts, but can also oxidize testosterone depending on conditions. These variations are important for designing isoform-selective inhibitors.
Key Genes Involved in GO:0047045 testosterone dehydrogenase (NADP+) activity
The following genes encode enzymes that exhibit testosterone dehydrogenase (NADP+) activity or are closely related to this function, based on published biochemical and structural studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AKR1C3 | NADP+-dependent 17beta-HSD (17beta-HSD5) that catalyzes testosterone oxidation and androstenedione reduction | Target for selective inhibitors in non-small cell lung cancer and prostate cancer |
| HSD17B1 | 17beta-HSD type 1, primarily NADP+-dependent, catalyzes estrone reduction but can also oxidize testosterone | Studied for roles in breast cancer and steroid metabolism |
| HSD17B2 | 17beta-HSD type 2, NAD+-dependent, inactivates testosterone to androstenedione | Contrasts with NADP+-dependent isoforms; used to study cofactor specificity |
| HSD17B3 | 17beta-HSD type 3, testis-specific, catalyzes androstenedione to testosterone (NADPH-dependent) | Mutations cause 17beta-HSD deficiency; model for androgen biosynthesis |
| HSD17B5 | Alternative name for AKR1C3; NADP+-dependent 17beta-HSD | Same as AKR1C3; studied in hormone-dependent cancers |
| AKR1C1 | Aldo-keto reductase that can exhibit 17beta-HSD activity with NADP+ | Related to benzene dihydrodiol dehydrogenase activity |
| AKR1C2 | Aldo-keto reductase with 17beta-HSD activity toward testosterone | Potential role in steroid hormone metabolism |
| AKR1C4 | Liver-specific aldo-keto reductase with 17beta-HSD activity | Studied for drug metabolism and steroid clearance |
| AKR1D1 | Delta-4-3-ketosteroid 5beta-reductase, not a 17beta-HSD but involved in steroid hormone clearance | Related to steroid metabolism but distinct from GO:0047045 |
| CYP17A1 | 17alpha-hydroxylase/17,20-lyase, upstream of 17beta-HSD in androgen synthesis | Provides substrates for 17beta-HSD; target in prostate cancer |
| SRD5A1 | 5alpha-reductase type 1, converts testosterone to dihydrotestosterone | Competes with 17beta-HSD for testosterone; relevant to androgen action |
| SRD5A2 | 5alpha-reductase type 2, converts testosterone to dihydrotestosterone | Same as above; mutations cause 5alpha-reductase deficiency |
| STS | Steroid sulfatase, hydrolyzes steroid sulfates to free steroids | Affects testosterone availability; studied in hormone-dependent cancers |
| SULT2A1 | Sulfotransferase that sulfates steroids including testosterone | Inactivates testosterone; balance with 17beta-HSD activity |
| UGT2B17 | UDP-glucuronosyltransferase that glucuronidates testosterone | Major route of testosterone elimination; affects androgen levels |
| NR3C4 | Androgen receptor, mediates testosterone signaling | Downstream effector; 17beta-HSD activity modulates AR activation |
| STAR | Steroidogenic acute regulatory protein, transports cholesterol to mitochondria | Upstream of testosterone synthesis; affects substrate availability |
| CYP11A1 | Cholesterol side-chain cleavage enzyme, first step in steroidogenesis | Provides precursors for testosterone; studied in steroidogenic tissues |
How Is testosterone dehydrogenase (NADP+) activity Regulated?
The activity of testosterone dehydrogenase (NADP+) is regulated at multiple levels. At the transcriptional level, expression of genes such as AKR1C3 and HSD17B isoforms is controlled by steroidogenic transcription factors and can be influenced by hormones and growth factors. Post-translational modifications, including phosphorylation, may alter enzyme activity or stability, although specific sites have not been fully mapped for all isoforms. The intracellular ratio of NADP+ to NADPH is a critical determinant of the reaction direction; conditions that increase NADP+ availability favor testosterone oxidation. Additionally, environmental chemicals such as triphenyltin and tributyltin can directly inhibit testicular 17beta-hydroxysteroid dehydrogenase activity, reducing testosterone biosynthesis. In cancer cells, AKR1C3 expression can be upregulated as a mechanism of resistance to EGFR inhibitors, suggesting that therapeutic pressure can select for increased NADP+-dependent 17beta-HSD activity.
testosterone dehydrogenase (NADP+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AKR1C3 | Non-small cell lung cancer, EGFR C797S-mediated osimertinib resistance | Knockout or point-mutation cell lines to test inhibitor sensitivity |
| HSD17B3 | 17beta-hydroxysteroid dehydrogenase type 3 deficiency, disorder of sex development | Knock-in of patient mutations in steroidogenic cell lines |
| HSD17B2 | Prostate cancer, androgen metabolism | Overexpression or knockout in prostate cancer cell lines |
| SRD5A2 | 5alpha-reductase deficiency, androgen insensitivity | Point-mutation knock-in models to study testosterone metabolism |
| CYP17A1 | Prostate cancer, congenital adrenal hyperplasia | Knockout or knock-in in adrenal and gonadal cell models |
Cancer and therapy resistance
NADP+-dependent 17beta-HSD activity, particularly that of AKR1C3, has been implicated in resistance to EGFR C797S-mediated osimertinib resistance in non-small cell lung cancer. Selective AKR1C3 inhibitors have been developed to overcome this resistance, highlighting the clinical importance of this enzymatic activity. In prostate cancer, intratumoral androgen synthesis via 17beta-HSD enzymes can fuel tumor growth even under castration conditions, making these enzymes therapeutic targets.
Endocrine disruption and reproductive toxicity
Organotin compounds such as triphenyltin and tributyltin inhibit pig testicular 17beta-hydroxysteroid dehydrogenase activity and suppress testosterone biosynthesis, demonstrating that environmental toxicants can disrupt this GO term and lead to reproductive dysfunction. This has implications for male fertility and endocrine health.
Steroidogenic disorders
Deficiencies in 17beta-hydroxysteroid dehydrogenase type 3, which catalyzes the reverse reaction (androstenedione to testosterone), cause a disorder of sex development. While this enzyme primarily uses NADPH for reduction, its interplay with NADP+-dependent oxidative enzymes affects the overall balance of testosterone and androstenedione. The cross-talk between adrenal and Leydig cell steroids further modulates this balance.
From testosterone dehydrogenase (NADP+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AKR1C3 restore sensitivity to osimertinib in EGFR C797S cells? | AKR1C3 knockout in NSCLC cell lines |
| How does a specific point mutation in HSD17B3 affect testosterone dehydrogenase activity? | Point-mutation knock-in in HEK293 or Leydig cell lines |
| Can overexpression of HSD17B2 reduce intracellular testosterone levels? | Overexpression of HSD17B2 in prostate cancer cell lines |
| What is the effect of organotin exposure on testicular 17beta-HSD activity? | Primary Leydig cell cultures or testicular explants treated with triphenyltin |
| Does tagging AKR1C3 with a fluorescent protein alter its subcellular localization? | Knock-in of tagged AKR1C3 in cancer cell lines |
| Can CRISPR library screening identify synthetic lethal partners with AKR1C3 inhibition? | Genome-wide CRISPR knockout library in AKR1C3-overexpressing cells |
How to Study the testosterone dehydrogenase (NADP+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADPH absorbance assay | Enzyme activity via NADPH production at 340 nm | Kinetic characterization of purified 17beta-HSD |
| Radioactive substrate assay | Conversion of 14C-testosterone to androstenedione | Tissue homogenate activity profiling |
| X-ray crystallography | Three-dimensional structure of enzyme-cofactor-substrate complex | Rational inhibitor design |
| CRISPR knockout | Loss-of-function effects on testosterone metabolism | Target validation in cancer cell lines |
| CRISPR point mutation | Effect of specific amino acid changes on catalysis | Mechanistic studies of active-site residues |
| Overexpression | Gain-of-function effects on androgen levels | Modeling enzyme upregulation in disease |
| RNA-seq | Transcriptional changes in steroidogenic genes | Pathway analysis in response to treatment |
| Metabolomics | Quantification of testosterone and androstenedione | Measuring flux through the pathway |
Enzymatic activity assays
Direct measurement of testosterone dehydrogenase (NADP+) activity is typically performed using spectrophotometric assays that monitor the formation of NADPH at 340 nm. These assays use purified enzyme or cell lysates and provide kinetic parameters such as Km and Vmax for testosterone and NADP+. Radioactive substrate assays with 14C-testosterone followed by thin-layer chromatography can also be used to separate and quantify products.
Structural biology
X-ray crystallography of enzymes in complex with testosterone and NADP+ has revealed the atomic details of substrate binding and catalysis. Structures of human 3alpha-hydroxysteroid dehydrogenase type 3 and 3alpha-hydroxysteroid/dihydrodiol dehydrogenase have provided templates for understanding how NADP+ is coordinated and how the steroid is oriented for hydride transfer. These structures are valuable for rational inhibitor design.
Cell-based models and CRISPR editing
CRISPR-Cas9 knockout, point mutation, and knock-in cell models allow researchers to study the consequences of altering specific genes on testosterone dehydrogenase activity. For example, knockout of AKR1C3 in cancer cell lines can be used to assess its contribution to drug resistance. Overexpression models can test whether increased enzyme levels alter intracellular androgen profiles.
Omics and bioinformatics
Transcriptomic and proteomic profiling can identify changes in expression of 17beta-HSD genes under different conditions. Bioinformatics analysis of public datasets can reveal correlations between enzyme expression and disease outcomes. These approaches are complemented by targeted metabolomics to quantify testosterone and androstenedione levels.
How CRISPR Can Be Used to Study GO:0047045 testosterone dehydrogenase (NADP+) activity
Knockout
CRISPR-Cas9 knockout of genes encoding NADP+-dependent 17beta-HSD enzymes, such as AKR1C3, can abolish testosterone dehydrogenase activity in cell models. This approach is used to determine whether loss of the enzyme sensitizes cancer cells to targeted therapies, as shown for EGFR C797S-mediated osimertinib resistance. Knockout models also help distinguish the contributions of different isoforms to total cellular activity.
Point Mutation
Introducing specific point mutations into the catalytic domain of 17beta-HSD enzymes can reveal critical residues for substrate binding or cofactor preference. For example, mutating the catalytic tyrosine or lysine can impair hydride transfer. Such models are valuable for understanding naturally occurring mutations that cause enzyme deficiency, such as in HSD17B3.
Knock-in
Knock-in of tagged versions of 17beta-HSD enzymes (e.g., GFP or FLAG) allows for real-time tracking of protein localization and interaction partners. Knock-in of disease-associated mutations can create isogenic models to study the impact on testosterone dehydrogenase activity and downstream androgen signaling.
Overexpression
Overexpression of NADP+-dependent 17beta-HSD enzymes in cell lines can mimic the elevated enzyme levels seen in some cancers and endocrine disorders. This approach is used to test whether increased testosterone oxidation alters cell proliferation, androgen receptor activation, or drug sensitivity.
How EDITGENE Supports testosterone dehydrogenase (NADP+) activity Research
Researchers studying testosterone dehydrogenase (NADP+) activity-related genes often need to determine whether a candidate gene is causally involved in androgen metabolism, drug resistance, or endocrine disruption. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models that enable such causal inferences.
Contact EDITGENE today to design your custom CRISPR model for testosterone dehydrogenase (NADP+) activity research.
Frequently Asked Questions About testosterone dehydrogenase (NADP+) activity
What is testosterone dehydrogenase (NADP+) activity?
It is the enzyme activity that catalyzes the NADP+-dependent oxidation of testosterone to androst-4-ene-3,17-dione, as defined by GO:0047045.
What genes are involved in testosterone dehydrogenase (NADP+) activity?
Genes such as AKR1C3, HSD17B1, HSD17B2, HSD17B3, and other aldo-keto reductases encode enzymes with this activity.
What is the reaction catalyzed by GO:0047045?
The reaction is NADP+ + testosterone = NADPH + H+ + androst-4-ene-3,17-dione.
Which cofactor does testosterone dehydrogenase (NADP+) use?
It uses NADP+ as the preferred electron acceptor, distinguishing it from NAD+-dependent isoforms.
How is testosterone dehydrogenase (NADP+) activity measured?
It is commonly measured by spectrophotometric assays monitoring NADPH formation at 340 nm or by radioactive substrate conversion assays.
What diseases are associated with testosterone dehydrogenase (NADP+) activity?
It has been linked to non-small cell lung cancer resistance to osimertinib, prostate cancer, and endocrine disruption by organotins.
Can CRISPR be used to study testosterone dehydrogenase (NADP+) activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes encoding this activity.
What is the role of AKR1C3 in testosterone dehydrogenase (NADP+) activity?
AKR1C3 (17beta-HSD5) is a NADP+-dependent enzyme that can oxidize testosterone and reduce androstenedione, and its inhibition is being explored in cancer therapy.
How does organotin exposure affect testosterone dehydrogenase (NADP+) activity?
Triphenyltin and tributyltin inhibit testicular 17beta-hydroxysteroid dehydrogenase activity, reducing testosterone biosynthesis.
What structural information is available for enzymes with this activity?
Crystal structures of human 3alpha-hydroxysteroid dehydrogenase type 3 and 3alpha-hydroxysteroid/dihydrodiol dehydrogenase in complex with testosterone and NADP+ have been solved.
Conclusion
GO:0047045, testosterone dehydrogenase (NADP+) activity, represents a critical enzymatic function in androgen metabolism with far-reaching implications for endocrinology, oncology, and toxicology. The NADP+-dependent oxidation of testosterone to androstenedione regulates hormone bioavailability and has been implicated in cancer therapy resistance and endocrine disruption. Structural and biochemical studies have provided a solid foundation for understanding the catalytic mechanism and for developing selective inhibitors. Continued research using CRISPR-engineered cell models and advanced omics will further elucidate the roles of this activity in health and disease.
References
- 1. Guo C et al.. 2026. Discovery of Highly Selective AKR1C3 Inhibitors to Overcome EGFR C797S-Mediated Osimertinib Resistance in Non-Small Cell Lung Cancer.. J Med Chem 69(6):6399-6428 PMID: 41612551
- 2. Stupans I et al.. 2000. Testosterone dehydrogenase activity in koala liver: characterisation of cofactor and steroid substrate differences.. Comp Biochem Physiol C Toxicol Pharmacol 125(2):245-50 PMID: 11790346
- 3. Hara A et al.. 1985. Guinea-pig liver testosterone 17 beta-dehydrogenase (NADP+) and aldehyde reductase exhibit benzene dihydrodiol dehydrogenase activity.. Biochem J 225(1):177-81 PMID: 2983661
- 4. Ohno S et al.. 2005. Triphenyltin and Tributyltin inhibit pig testicular 17beta-hydroxysteroid dehydrogenase activity and suppress testicular testosterone biosynthesis.. Steroids 70(9):645-51 PMID: 15899506
- 5. Wang Y et al.. 2019. The cross talk of adrenal and Leydig cell steroids in Leydig cells.. J Steroid Biochem Mol Biol 192:105386 PMID: 31152782
- 6. Kaguera E et al.. 1977. Purification and properties of a new testosterone 17beta-dehydrogenase (NADP+) from guinea-pig liver.. Biochem J 163(3):401-7 PMID: 18133
- 7. Nahoum V et al.. 2001. Structure of the human 3alpha-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25-A resolution.. J Biol Chem 276(45):42091-8 PMID: 11514561
- 8. Bennett MJ et al.. 1997. Steroid recognition and regulation of hormone action: crystal structure of testosterone and NADP+ bound to 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase.. Structure 5(6):799-812 PMID: 9261071
